You now have access to all the content in the PAREXEL Access Hub. We look forward to engaging with you.
We will be in touch shortly.
Please complete our registration form to continue.
Collating the right kind of economic data will make the most of late phase studies. Real-world analysis, conducted with an experienced late phase partner, will build a robust argument for reimbursement and help bring your new drug to market, faster.
Real data, such as actual costs when the drug is in use and the observed impact the product has on the quality of life for patients, is the late phase data payers want to see.
For smooth pharmaceutical product development and effective market access strategy, you need a partner that offers an integrated solution for late phase clinical research, such as PAREXEL.
Engaging one partner throughout the drug development process not only reduces costs over time, but increases accountability and commitment.
Regulatory & Payer Submissions